Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein

Abstract

Background SARS-CoV-2 is a recently emerged respiratory pathogen that has significantly impacted global human health. We wanted to rapidly characterise the transcriptomic, proteomic and phosphoproteomic landscape of this novel coronavirus to provide a fundamental description of the virus’s genomic and proteomic potential. Methods We used direct RNA sequencing to determine the transcriptome of SARS-CoV-2 grown in Vero E6 cells which is widely used to propagate the novel coronavirus. The viral transcriptome was analysed using a recently developed ORF-centric pipeline. Allied to this, we used tandem mass spectrometry to investigate the proteome and phosphoproteome of the same virally infected cells. Results Our integrated analysis revealed that the viral transcripts (i.e. subgenomic mRNAs) generally fitted the expected transcription model for coronaviruses. Importantly, a 24 nt in-frame deletion was detected in over half of the subgenomic mRNAs encoding the spike (S) glycoprotein and was predicted to remove a proposed furin cleavage site from the S glycoprotein. Tandem mass spectrometry identified over 500 viral peptides and 44 phosphopeptides in virus-infected cells, covering almost all proteins predicted to be encoded by the SARS-CoV-2 genome, including peptides unique to the deleted variant of the S glycoprotein. Conclusions Detection of an apparently viable deletion in the furin cleavage site of the S glycoprotein, a leading vaccine target, shows that this and other regions of SARS-CoV-2 proteins may readily mutate. The furin site directs cleavage of the S glycoprotein into functional subunits during virus entry or exit and likely contributes strongly to the pathogenesis and zoonosis of this virus. Our data emphasises that the viral genome sequence should be carefully monitored during the growth of viral stocks for research, animal challenge models and, potentially, in clinical samples. Such variations may result in different levels of virulence, morbidity and mortality.

Cited by papers we hold 28

• The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics · 2023
  No notice
• Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab · 2022
  Not checked
• SARS-CoV-2 Diagnostics Based on Nucleic Acids Amplification: From Fundamental Concepts to Applications and Beyond · 2022
  Not checked
• The dynamics of SARS-CoV-2 infectivity with changes in aerosol microenvironment · 2022
  No notice
• Nucleocapsid mutations in SARS-CoV-2 augment replication and pathogenesis · 2022
  No notice
• Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential · 2021
  No notice
• Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency · 2021
  Not checked
• Can SARS-CoV-2 Virus Use Multiple Receptors to Enter Host Cells? · 2021
  No notice
• From Plant Survival Under Severe Stress to Anti-Viral Human Defense – A Perspective That Calls for Common Efforts · 2021
  Not checked
• SARS-CoV-2: from its discovery to genome structure, transcription, and replication · 2021
  No notice
• The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease · 2021
  Corrected
• Liquid–liquid phase separation in human health and diseases · 2021
  No notice
• SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells · 2021
  No notice
• In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2 · 2021
  No notice
• SARS‐CoV‐2 sensing by RIG‐I and MDA5 links epithelial infection to macrophage inflammation · 2021
  No notice
• A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research · 2021
  No notice
• SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 Sarbecovirus genomes · 2021
  No notice
• SARS-CoV-2 one year on: evidence for ongoing viral adaptation · 2021
  No notice
• Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity · 2021
  No notice
• The Polybasic Cleavage Site in SARS-CoV-2 Spike Modulates Viral Sensitivity to Type I Interferon and IFITM2 · 2021
  No notice

and 8 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.